| Q28489107 | 2,2'-diphenyl-3,3'-diindolylmethane: a potent compound induces apoptosis in breast cancer cells by inhibiting EGFR pathway |
| Q38399733 | A High-Affinity Repebody for Molecular Imaging of EGFR-Expressing Malignant Tumors |
| Q34460938 | A Meta-Analysis on the Relations between EGFR R521K Polymorphism and Risk of Cancer |
| Q41738897 | A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma |
| Q39643088 | A Novel Magneto-fluorescent Nano-bioprobe for Cancer Cell Targeting, Imaging and Collection |
| Q40690113 | A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. |
| Q36445112 | A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans |
| Q90435196 | A bioactivatable self-quenched nanogel for targeted photodynamic therapy |
| Q38683823 | A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants |
| Q42634026 | A co-module approach for elucidating drug-disease associations and revealing their molecular basis |
| Q54521295 | A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma. |
| Q34325538 | A comprehensive continuous-time model for the appearance of CGH signal due to chromosomal missegregations during mitosis |
| Q36488342 | A critical appraisal of prognostic and predictive factors for common lung cancers. |
| Q35104763 | A decade of tyrosine kinases: from gene discovery to therapeutics |
| Q35017006 | A four-gene signature predicts disease progression in muscle invasive bladder cancer. |
| Q92058331 | A link between a synonymous SNP and the clinical response to tyrosine kinase inhibitors |
| Q35220132 | A mathematical model of glioblastoma tumor spheroid invasion in a three-dimensional in vitro experiment |
| Q34084021 | A molecular prognostic model predicts esophageal squamous cell carcinoma prognosis |
| Q34470390 | A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor |
| Q46597381 | A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer |
| Q92382708 | A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer |
| Q35238406 | A pharmacological primer of biased agonism |
| Q80101024 | A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer |
| Q48320672 | A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. |
| Q36480044 | A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole. |
| Q36696463 | A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. |
| Q34478770 | A pilot characterization of human lung NSCLC by protein pathway activation mapping |
| Q39975984 | A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas |
| Q90271846 | A predictive computational model reveals that GIV/girdin serves as a tunable valve for EGFR-stimulated cyclic AMP signals |
| Q64096053 | A preliminary investigation of circulating extracellular vesicles and biomarker discovery associated with treatment response in head and neck squamous cell carcinoma |
| Q55717412 | A prospective study on neoadjuvant chemoradiotherapy plus anti-EGFR monoclonal antibody followed by surgery for locally advanced cervical cancer. |
| Q34081624 | A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. |
| Q35584153 | A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy |
| Q36951089 | A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis |
| Q40535662 | Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules |
| Q43917572 | Ablation of breast cancer cells using trastuzumab-functionalized multi-walled carbon nanotubes and trastuzumab-diphtheria toxin conjugate. |
| Q33688285 | Accounting for pharmacokinetic differences in dual-tracer receptor density imaging. |
| Q53217202 | Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP). |
| Q38494311 | Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. |
| Q33942266 | Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. |
| Q46915052 | Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib |
| Q34727996 | Activation of epidermal growth factor receptor is required for Chlamydia trachomatis development |
| Q39346046 | Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model". |
| Q34129430 | Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands |
| Q36696568 | Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro |
| Q45947690 | Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering. |
| Q39091817 | Advanced gastric adenocarcinoma: optimizing therapy options. |
| Q37489942 | Advances in preclinical small molecules for the treatment of NSCLC. |
| Q26860343 | Advances of hypoxia and lung cancer |
| Q33983656 | Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer |
| Q38857343 | Afatinib inhibits proliferation and invasion and promotes apoptosis of the T24 bladder cancer cell line |
| Q36742355 | Alpha internexin expression related with molecular characteristics in adult glioblastoma and oligodendroglioma |
| Q38632962 | Alterations in Gene Expression of Components of the Renin-Angiotensin System and Its Related Enzymes in Lung Cancer. |
| Q33411775 | Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines |
| Q53644641 | Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry. |
| Q35623065 | An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells |
| Q58105553 | An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: Potential in esophageal squamous cell carcinoma and other malignancies |
| Q53222808 | An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis. |
| Q38518964 | An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. |
| Q34766967 | An internal ribosome entry site in the 5' untranslated region of epidermal growth factor receptor allows hypoxic expression |
| Q46408397 | Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma |
| Q61809501 | Analysis of Progress and Challenges of EGFR-Targeted Molecular Imaging in Cancer With a Focus on Affibody Molecules |
| Q31037039 | Analysis of differentially expressed genes based on microarray data of glioma |
| Q40564623 | Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas |
| Q36695371 | Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer |
| Q39368829 | Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis. |
| Q53121293 | Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents. |
| Q39955173 | Anti-EGFR activation, anti-proliferative and pro-apoptotic effects of polyclonal antibodies induced by EGFR-based cancer vaccine |
| Q42376374 | Anti-EGFR antibody conjugated silica nanoparticles as probes for lung cancer detection |
| Q37687445 | Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. |
| Q38730179 | Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells |
| Q36425973 | Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice. |
| Q42119902 | Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept |
| Q35623056 | Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells |
| Q36369268 | Antibody-nanoparticle conjugates to enhance the sensitivity of ELISA-based detection methods |
| Q33575434 | Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model |
| Q34792693 | Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. |
| Q34442958 | Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses |
| Q35673895 | Aptamer technology for tracking cells' status & function |
| Q37274280 | Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer |
| Q89539308 | Assessment of the SRC Inhibition Role in the Efficacy of Breast Cancer Radiotherapy |
| Q64105444 | Assessment of tumor promoting effects of amniotic and umbilical cord mesenchymal stem cells in vitro and in vivo |
| Q34650974 | Association among polymorphisms in EGFR gene exons, lifestyle and risk of gastric cancer with gender differences in Chinese Han subjects |
| Q44295790 | Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. |
| Q26866067 | At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone |
| Q51791907 | Atypical and malignant hidradenomas: a histological and immunohistochemical study. |
| Q90533257 | BCAP31 drives TNBC development by modulating ligand-independent EGFR trafficking and spontaneous EGFR phosphorylation |
| Q36539643 | BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function |
| Q40101895 | Bacterial Toxins for Cancer Therapy |
| Q42499937 | Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates |
| Q35206946 | Beyond Herceptin and Gleevec |
| Q38222512 | Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer |
| Q33753135 | Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors |
| Q93054476 | Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation |
| Q39814222 | Biological characteristics of a specific brain metastatic cell line derived from human lung adenocarcinoma |
| Q24685049 | Biological response modifiers in cancer |
| Q34094855 | Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). |
| Q50046541 | Biomarker threshold adaptive designs for survival endpoints. |
| Q37378581 | Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer |
| Q51393032 | Biosensing made easy with PEG-targeted bi-specific antibodies. |
| Q64095664 | Bladder cancer cells interact with vascular endothelial cells triggering EGFR signals to promote tumor progression |
| Q36552741 | Blockade of phospholipid scramblase 1 with its N-terminal domain antibody reduces tumorigenesis of colorectal carcinomas in vitro and in vivo |
| Q39720186 | Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF. |
| Q36558683 | Blood-brain barrier and chemotherapeutic treatment of brain tumors |
| Q34793288 | Calpains as potential anti-cancer targets |
| Q38431604 | Cancer nanotherapeutics in clinical trials. |
| Q36563677 | Cancer of the gastroesophageal junction: Current therapy options |
| Q38099726 | Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial |
| Q57060886 | Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling |
| Q48704352 | Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma |
| Q46816802 | Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma |
| Q54483949 | Cetuximab in combination with anti-human IgG antibodies efficiently down-regulates the EGF receptor by macropinocytosis. |
| Q37290499 | Cetuximab in the management of colorectal cancer |
| Q36717359 | Cetuximab in the treatment of metastatic colorectal cancer |
| Q37118923 | Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer |
| Q34623949 | Cetuximab: a review of its use in squamous cell carcinoma of the head and neck |
| Q54458675 | Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer. |
| Q52649596 | Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab. |
| Q30429640 | Characterization of novel synthesized small molecular compounds against non-small cell lung cancer |
| Q38699840 | Characterizing the detection threshold for optical imaging in surgical oncology. |
| Q28073246 | Chemoresistance and targeted therapies in ovarian and endometrial cancers |
| Q58123533 | Chemotaxis Model for Breast Cancer Cells Based on Signal/Noise Ratio |
| Q37195581 | Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice |
| Q42510237 | Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan |
| Q34095748 | Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer |
| Q36442340 | Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up |
| Q36111249 | Clinical applications for targeted therapy in bladder cancer |
| Q47682948 | Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue |
| Q35008670 | Clinical relevance of molecular markers in lung cancer. |
| Q35078032 | Clinical significance and usefulness of soluble heparin binding-epidermal growth factor in gastric cancer. |
| Q80100958 | Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib |
| Q36614705 | Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma |
| Q36085847 | Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance |
| Q54979642 | Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer. |
| Q35114983 | Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival |
| Q46589779 | Cofilin 1 promotes bladder cancer and is regulated by TCF7L2. |
| Q34465240 | Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer |
| Q36055257 | Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer |
| Q36189311 | Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation. |
| Q36996324 | Combining chemotherapy and targeted therapies in metastatic colorectal cancer |
| Q61711535 | Comparison of Kinetic Models for Dual-Tracer Receptor Concentration Imaging in Tumors |
| Q94453279 | Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR-tyrosine kinase inhibitor treatment in patients with non-small cell lung cancer from different ethnic groups |
| Q82801750 | Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa |
| Q42173012 | Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome |
| Q54976942 | Composite regulation of ERK activity dynamics underlying tumour-specific traits in the intestine. |
| Q89763784 | Comprehensive pharmacogenomic characterization of gastric cancer |
| Q37671783 | Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers |
| Q37284069 | Conservation of protein abundance patterns reveals the regulatory architecture of the EGFR-MAPK pathway |
| Q42198695 | Correlation between expressions of Cyclin-D1, EGFR and p53 with chemoradiation response in patients of locally advanced oral squamous cell carcinoma |
| Q34252140 | Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC. |
| Q37717281 | Correlation of EGFR, pEGFR and p16INK4 expressions and high risk HPV infection in HIV/AIDS-related squamous cell carcinoma of conjunctiva |
| Q37573906 | Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer |
| Q46434054 | Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab. |
| Q42795830 | Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor |
| Q26740067 | Current targeted therapies in the treatment of advanced colorectal cancer: a review |
| Q53493024 | Cyclic-AMP-dependent protein kinase (PKA) activity assay based on FRET between cationic conjugated polymer and chromophore-labeled peptide. |
| Q41815580 | Cytokines and growth factors expressed by human cutaneous melanoma |
| Q38089767 | Cytokines as potential tumour markers. |
| Q59800908 | Cytotoxicity of nimbolide towards multidrug-resistant tumor cells and hypersensitivity via cellular metabolic modulation |
| Q37834359 | Defining the cancer master switch |
| Q43269855 | Dendritic cells pulsed with GST-EGFR fusion protein: effect in antitumor immunity against head and neck squamous cell carcinoma |
| Q37307506 | Derailed endocytosis: an emerging feature of cancer |
| Q101404496 | Design, synthesis, and computational study of hybrid quinazoline 1,3,5-triazines as epidermal growth factor receptor (EGFR) inhibitors with anticancer activity |
| Q36879532 | Detection and imaging of aggressive cancer cells using an epidermal growth factor receptor (EGFR)-targeted filamentous plant virus-based nanoparticle |
| Q33868284 | Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma |
| Q48589913 | Development of a knowledge assessment tool for dermatotoxicity caused by inhibitors of epidermal growth factor receptor |
| Q79284320 | Different expression patterns of KIT, EGFR, and HER‐2 (c‐erbB‐2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma |
| Q41778604 | Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines |
| Q34177894 | Differential regulation of EGFR-MAPK signaling by deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA) in colon cancer |
| Q48241016 | Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation |
| Q36951801 | Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. |
| Q33569818 | Distinct roles for Rho versus Rac/Cdc42 GTPases downstream of Vav2 in regulating mammary epithelial acinar architecture |
| Q42484909 | Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants |
| Q93036043 | Diverse roles of epidermal growth factors receptors in oral and cutaneous canine melanomas |
| Q34572101 | Does phosphorylation of cofilin affect the progression of human bladder cancer? |
| Q33912974 | Down-regulation of epidermal growth factor receptor by selective expansion of a 5'-end regulatory dinucleotide repeat in colon cancer with microsatellite instability |
| Q92241294 | DpdtbA-Induced Growth Inhibition in Human Esophageal Cancer Cells Involved Inactivation of the p53/EGFR/AKT Pathway |
| Q33860674 | Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells |
| Q39845394 | Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition |
| Q36999193 | Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate? |
| Q38232035 | Dynamic contrast-enhanced MRI of gastric cancer: Correlation of the perfusion parameters with pathological prognostic factors |
| Q39350198 | E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by pioglitazone in a preclinical model. |
| Q33667547 | EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation |
| Q47156089 | EGF receptor signaling, phosphorylation, ubiquitylation and endocytosis in tumors in vivo |
| Q29619032 | EGF-ERBB signalling: towards the systems level |
| Q37445118 | EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. |
| Q37240726 | EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer |
| Q46411995 | EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer |
| Q34712741 | EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features |
| Q36419182 | EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? |
| Q44306493 | EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor |
| Q47696736 | EGFR expression in circulating tumor cells from high-grade Metastatic Sarcomas. |
| Q33814702 | EGFR immunoexpression, RAS immunoexpression and their effects on survival in lung adenocarcinoma cases |
| Q39586032 | EGFR in melanoma: clinical significance and potential therapeutic target |
| Q37767383 | EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. |
| Q44068440 | EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma |
| Q26852507 | EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer |
| Q34167004 | EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysis |
| Q53264287 | EGFR overexpression in canine primary lung cancer: pathogenetic implications and impact on survival. |
| Q51794333 | EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. |
| Q37217464 | EGFR regulates macrophage activation and function in bacterial infection |
| Q38171032 | EGFR signaling and autophagy dependence for growth, survival, and therapy resistance |
| Q38968246 | EGFR signaling downstream of EGF regulates migration, invasion, and MMP secretion of immortalized cells derived from human ameloblastoma |
| Q36872290 | EGFR targeting of solid tumors |
| Q58134841 | EGFR-Signaling and Autophagy: How they Fit in the Cancer Landscape |
| Q36962490 | EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma |
| Q38926814 | EGFR-mediated macrophage activation promotes colitis-associated tumorigenesis. |
| Q45871491 | EGFR-targeted therapies in the post-genomic era. |
| Q48150178 | EGFRvIII expression triggers a metabolic dependency and therapeutic vulnerability sensitive to autophagy inhibition |
| Q35202837 | ENTPD5 induces apoptosis in lung cancer cells via regulating caspase 3 expression |
| Q35571704 | Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer |
| Q37388719 | Effect of epidermal growth factor receptor status on the outcomes of patients with metastatic gastric cancer: A pilot study |
| Q37426890 | Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. |
| Q33866870 | Emerging therapies in gastrointestinal cancers |
| Q36616502 | Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR |
| Q47872054 | Enhanced EGFR Targeting Activity of Plasmonic Nanostructures with Engineered GE11 Peptide. |
| Q92454757 | Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC) |
| Q58567008 | Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation |
| Q42928058 | Epidermal Growth Factor Receptor neddylation is regulated by a desmosomal-COP9 (Constitutive Photomorphogenesis 9) signalosome complex. |
| Q37734315 | Epidermal growth factor induces platelet-activating factor production through receptors transactivation and cytosolic phospholipase A2 in ovarian cancer cells |
| Q28485910 | Epidermal growth factor protects squamous cell carcinoma against cisplatin-induced cytotoxicity through increased interleukin-1β expression |
| Q35162373 | Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. |
| Q33631730 | Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung carcinoma |
| Q58603542 | Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China |
| Q34988074 | Epidermal growth factor receptor and bladder cancer |
| Q81322527 | Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma |
| Q42315381 | Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours |
| Q49335412 | Epidermal growth factor receptor aptamer-conjugated polymer-lipid hybrid nanoparticles enhance salinomycin delivery to osteosarcoma and cancer stem cells |
| Q37875223 | Epidermal growth factor receptor as a therapeutic target in veterinary oncology |
| Q24236143 | Epidermal growth factor receptor blockers for the treatment of ovarian cancer |
| Q24240523 | Epidermal growth factor receptor blockers for the treatment of ovarian cancer |
| Q24240840 | Epidermal growth factor receptor blockers for the treatment of ovarian cancer |
| Q57456685 | Epidermal growth factor receptor blockers for the treatment of ovarian cancer |
| Q34097126 | Epidermal growth factor receptor downregulation by small heterodimeric binding proteins |
| Q46371923 | Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy |
| Q34411696 | Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study |
| Q35761590 | Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma |
| Q47791804 | Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system |
| Q33691211 | Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes |
| Q42497473 | Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma. |
| Q44485092 | Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer |
| Q54538613 | Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. |
| Q73470620 | Epidermal growth factor receptor is a marker for syncytiotrophoblastic cells in testicular germ cell tumors |
| Q33824203 | Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity |
| Q29615474 | Epidermal growth factor receptor mutations in lung cancer |
| Q54601144 | Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations. |
| Q35870351 | Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma |
| Q39345249 | Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model |
| Q34159125 | Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck |
| Q24653036 | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues |
| Q38852900 | Epidermal growth factor receptor-targeted peptide conjugated phospholipid micelles for doxorubicin delivery |
| Q44497086 | Epidermal growth factor receptors (EGFR): a new target for anticancer therapy |
| Q36121103 | Epithelial cell identity in hyperplastic precursors of breast cancer |
| Q47974787 | ErbB Receptors and Cancer |
| Q36545883 | ErbB receptor negative regulatory mechanisms: implications in cancer |
| Q37249978 | ErbBs in lung cancer |
| Q35160181 | Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase |
| Q38841850 | Erlotinib and gefitinib responsiveness in head and neck cancer cell lines--a comparing analysis with cetuximab. |
| Q37574936 | Erlotinib in a patient with vaginal carcinoma and pulmonary metastasis: A case report |
| Q35558557 | Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab |
| Q91473462 | Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRβ-IL-6 axis in MUC1-positive cervical cancer |
| Q36605522 | Erlotinib resistance in lung cancer: current progress and future perspectives |
| Q54777001 | Erlotinib: applications in therapy and current status of research. |
| Q38829535 | Esculetin Induces Apoptosis Through EGFR/PI3K/Akt Signaling Pathway and Nucleophosmin Relocalization. |
| Q24537669 | Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4. |
| Q39955876 | Establishment and characterization of a cell line (IGSK-3) secreting human chorionic gonadotropin, adrenocorticotropic hormone and parathyroid hormone-related protein derived from primary poorly differentiated adenocarcinoma of the stomach |
| Q39773465 | Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2. |
| Q37040850 | Evaluating the Prevalence of the Epidermal Growth Factor Receptor in Transitional Cell Carcinoma of Bladder and its Relationship With Other Prognostic Factors |
| Q37206267 | Evaluation of EGFR as a prognostic and diagnostic marker for head and neck squamous cell carcinoma patients |
| Q27851592 | Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study |
| Q53602019 | Evaluation of involved proteins in colon adenocarcinoma: an interactome analysis. |
| Q39716869 | Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. |
| Q37446067 | Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer |
| Q59329233 | Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium |
| Q24803435 | Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization |
| Q26828930 | Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities |
| Q38995370 | Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway |
| Q83855416 | Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma |
| Q52714617 | Expression of HNF4G and its potential functions in lung cancer. |
| Q40117486 | Expression of Rab5a in hepatocellular carcinoma: Possible involvement in epidermal growth factor signaling |
| Q38845254 | Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy |
| Q79522451 | Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome |
| Q33592904 | Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma |
| Q35803941 | Expression of the estrogen receptor α, progesterone receptor and epidermal growth factor receptor in papillary thyroid carcinoma tissues |
| Q37360495 | Extensive experience of disease control with gefitinib and the role of prognostic markers |
| Q38989275 | Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery |
| Q47778400 | Extracellular vesicles as drivers of epithelial-mesenchymal transition and carcinogenic characteristics in normal prostate cells. |
| Q39884252 | F84, a quinazoline derivative, exhibits high potent antitumor activity against human gynecologic malignancies |
| Q64114238 | FBXW2 suppresses migration and invasion of lung cancer cells via promoting β-catenin ubiquitylation and degradation |
| Q42115308 | Feasibility study of brain tumor delineation using immunolabeled gold nanorods |
| Q37771245 | First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab |
| Q30419853 | Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer |
| Q38612255 | Formulations of deoxycholic for therapy: a patent review (2011 - 2014). |
| Q37209926 | Frequent mutations of the CA simple sequence repeat in intron 1 of EGFR in mismatch repair-deficient colorectal cancers |
| Q37698244 | From bench to bedside: the growing use of translational research in cancer medicine. |
| Q55093479 | From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo. |
| Q26853233 | G Protein-Coupled Receptor Signaling in Stem Cells and Cancer |
| Q46289176 | GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways. |
| Q38749499 | GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma Metastasis |
| Q30155572 | GRB2 couples RhoU to epidermal growth factor receptor signaling and cell migration |
| Q36613924 | Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer |
| Q37522211 | Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study. |
| Q54564062 | Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response. |
| Q46650874 | Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania |
| Q30544631 | Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study |
| Q36629392 | Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models |
| Q39083974 | Generalized paired-agent kinetic model for in vivo quantification of cancer cell-surface receptors under receptor saturation conditions |
| Q37101367 | Genetic and chemical targeting of epithelial-restricted with serine box reduces EGF receptor and potentiates the efficacy of afatinib |
| Q33779432 | Genetic variants of EGF and VEGF predict prognosis of patients with advanced esophageal squamous cell carcinoma |
| Q35072797 | Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy |
| Q92374402 | Genome-wide DNA copy number profiling and bioinformatics analysis of ovarian cancer reveals key genes and pathways associated with distinct invasive/migratory capabilities |
| Q39643103 | Global molecular dysfunctions in gastric cancer revealed by an integrated analysis of the phosphoproteome and transcriptome |
| Q39108385 | Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenografts |
| Q36821175 | Globoside promotes activation of ERK by interaction with the epidermal growth factor receptor |
| Q37632159 | Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy |
| Q33663674 | GnRH-(1-5) transactivates EGFR in Ishikawa human endometrial cells via an orphan G protein-coupled receptor |
| Q36814491 | Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. |
| Q33699007 | HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation |
| Q36061145 | HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. |
| Q36724623 | HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder |
| Q41767530 | HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285. |
| Q34974682 | HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging |
| Q35827746 | HMMvar-func: a new method for predicting the functional outcome of genetic variants |
| Q52716394 | HOXA4, down-regulated in lung cancer, inhibits the growth, motility and invasion of lung cancer cells. |
| Q38469746 | Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective |
| Q80062040 | Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome |
| Q36393289 | Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells |
| Q35769805 | High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC) |
| Q33336861 | High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies |
| Q39934851 | High speed digital protein interaction analysis using microfluidic single molecule detection system |
| Q36449863 | High-sensitivity epidermal growth factor receptor immunostaining for colorectal carcinomas, compared with EGFR PharmDx™: a study of diagnostic accuracy |
| Q42847064 | Highly Sensitive Electrogenerated Chemiluminescence Biosensor in Profiling Protein Kinase Activity and Inhibition Using Gold Nanoparticle as Signal Transduction Probes |
| Q47589765 | Highly sensitive detection of epidermal growth factor receptor in lung cancer cells by aptamer-based target-/probe-mediated cyclic signal amplification |
| Q37379240 | Hydrogel-based protein array for quantifying epidermal growth factor receptor activity in cell lysates |
| Q39438159 | Hyperspectral molecular imaging of multiple receptors using immunolabeled plasmonic nanoparticles |
| Q38659248 | ICRP Publication 131: Stem Cell Biology with Respect to Carcinogenesis Aspects of Radiological Protection |
| Q24655085 | Identification of a Sam68 ribonucleoprotein complex regulated by epidermal growth factor |
| Q35806672 | Identification of an AAA ATPase VPS4B-dependent pathway that modulates epidermal growth factor receptor abundance and signaling during hypoxia. |
| Q40502210 | IkappaBalphaM suppresses angiogenesis and tumorigenesis promoted by a constitutively active mutant EGFR in human glioma cells |
| Q33962349 | Illuminating epidermal growth factor receptor densities on filopodia through plasmon coupling |
| Q36662662 | Imaging characteristics of stage I non-small cell lung cancer on CT and FDG-PET: relationship with epidermal growth factor receptor protein expression status and survival |
| Q55032160 | Immune Landscape of Breast Cancers. |
| Q35623476 | Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for Immunotherapy |
| Q39399928 | Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. |
| Q43001429 | Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma |
| Q37003601 | Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma |
| Q35770249 | Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation |
| Q34158993 | Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma |
| Q38633525 | Immunotherapy and targeted therapy for cervical cancer: an update |
| Q38367414 | Immunotherapy for lung cancer: for whom the bell tolls? |
| Q26751473 | Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers |
| Q34258399 | Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis |
| Q37602294 | Impact of molecular markers on treatment selection in advanced colorectal cancer |
| Q33289414 | Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells |
| Q37118974 | Implications of EGFR PharmDx kit for cetuximab eligibility |
| Q100750039 | Importin 13 promotes NSCLC progression by mediating RFPL3 nuclear translocation and hTERT expression upregulation |
| Q97542367 | Improved survival analysis by learning shared genomic information from pan-cancer data |
| Q35803276 | In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domain. |
| Q39370112 | In vitro targeted imaging and delivery of camptothecin using cetuximab-conjugated multifunctional PLGA-ZnS nanoparticles |
| Q30372076 | In vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft. |
| Q40825640 | In-depth N-glycome profiling of paired colorectal cancer and non-tumorigenic tissues reveals cancer-, stage- and EGFR-specific protein N-glycosylation. |
| Q35828611 | Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer. |
| Q36295330 | Inhibition of EGFR autophosphorylation plays an important role in the anti-breast cancer efficacy of the dithiocarbamate derivative TM208. |
| Q51137512 | Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer. |
| Q34405324 | Inhibition of EGFR-AKT axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model |
| Q92702959 | Inhibition of Oncogenic Kinases: An In Vitro Validated Computational Approach Identified Potential Multi-Target Anticancer Compounds |
| Q36640322 | Initial evidence for Sec62 as a prognostic marker in advanced head and neck squamous cell carcinoma. |
| Q50126142 | Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment. |
| Q92570530 | Integrative Analysis of Cancer Omics Data for Prognosis Modeling |
| Q39635376 | Integrin beta1 over‐expression associates with resistance to tyrosine kinase inhibitor gefitinib in non‐small cell lung cancer |
| Q39990738 | Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity |
| Q37289601 | Intestinal phenotype in mice overexpressing a heparin-binding EGF-like growth factor transgene in enterocytes |
| Q39253894 | Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment. |
| Q57003964 | Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours |
| Q49892584 | Investigation of major genetic alterations in neuroblastoma. |
| Q36736349 | Investigational agents against platinum-resistant ovarian cancer |
| Q53551081 | Is EGFR a moving target during radiotherapy of carcinoma of the uterine cervix? |
| Q36100844 | KRAS mutant colorectal tumors: past and present |
| Q48140493 | KRAS mutations in microsatellite instable gastric tumours: impact of targeted treatment and intratumoural heterogeneity |
| Q35190688 | Kernel machine approach to testing the significance of multiple genetic markers for risk prediction |
| Q64988694 | Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors. |
| Q49887882 | Kinase-targeted cancer therapies: progress, challenges and future directions |
| Q37398646 | Knock-down of amphiregulin inhibits cellular invasion in inflammatory breast cancer |
| Q33251283 | Label-free and real-time cell-based kinase assay for screening selective and potent receptor tyrosine kinase inhibitors using microelectronic sensor array |
| Q39400167 | Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity |
| Q37755493 | Lack of Cetuximab induced skin toxicity in a previously irradiated field: case report and review of the literature |
| Q54562020 | Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. |
| Q46965909 | Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer |
| Q37355729 | Lapatinib: new opportunities for management of breast cancer |
| Q92406179 | Lipid Profile and Aquaporin Expression under Oxidative Stress in Breast Cancer Cells of Different Malignancies |
| Q30596483 | Liquid crystal droplet-based amplification of microvesicles that are shed by mammalian cells |
| Q28261746 | Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility |
| Q35144727 | Long-term cultured human neural stem cells undergo spontaneous transformation to tumor-initiating cells |
| Q53622278 | Loss of EGF-dependent cell proliferation ability on radioresistant cell HepG2-8960-R. |
| Q39690739 | Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins |
| Q33861083 | Lung cancer cytology: potential pitfalls and mimics - a review |
| Q34570799 | Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance |
| Q34047878 | Masked Chimeric Antigen Receptor for Tumor-Specific Activation |
| Q57105786 | Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer |
| Q36395100 | Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer |
| Q26745689 | Mechanisms underlying skin disorders induced by EGFR inhibitors |
| Q38427102 | Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man. |
| Q102220522 | Metabolic glycan labelling for cancer-targeted therapy |
| Q41343483 | MicroRNA-107-5p suppresses non-small cell lung cancer by directly targeting oncogene epidermal growth factor receptor |
| Q39433270 | MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact |
| Q33590704 | MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer |
| Q38003048 | MicroRNAs in pancreatic cancer metabolism |
| Q34473944 | Microscopic lymph node tumor burden quantified by macroscopic dual-tracer molecular imaging |
| Q30836260 | Microscopic simulation of membrane molecule diffusion on corralled membrane surfaces. |
| Q31151322 | Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR. |
| Q35218002 | Mode of action of docetaxel - a basis for combination with novel anticancer agents |
| Q28484612 | Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression |
| Q36437230 | Modular nanotransporters: a versatile approach for enhancing nuclear delivery and cytotoxicity of Auger electron-emitting 125I. |
| Q56872060 | Modular pore-forming immunotoxins with caged cytotoxicity tailored by directed evolution |
| Q34489245 | Modulating the structure of EGFR with UV light: new possibilities in cancer therapy |
| Q58700723 | Molecular Diagnostics in Clinical Oncology |
| Q51019080 | Molecular alterations of EGFR in small intestinal adenocarcinoma. |
| Q38672075 | Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention. |
| Q33969308 | Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study |
| Q36370600 | Molecular diagnostics of non-small cell lung cancer using mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration |
| Q37825149 | Molecular imaging metrics to evaluate response to preclinical therapeutic regimens |
| Q30612000 | Molecular imaging of cancer cells using a bacteriophage-based 129Xe NMR biosensor |
| Q24678564 | Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin |
| Q35001415 | Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab |
| Q38562903 | Molecular mechanisms of squamous differentiation in urothelial cell carcinoma: a paradigm for molecular subtyping of urothelial cell carcinoma of the bladder |
| Q36772562 | Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer |
| Q38107276 | Molecularly targeted therapies for nonmelanoma skin cancers |
| Q35698114 | Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer |
| Q36032533 | Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma |
| Q40808615 | Multiple differential expression networks identify key genes in rectal cancer |
| Q30474840 | Multiplex photoacoustic molecular imaging using targeted silica-coated gold nanorods |
| Q38804094 | Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients. |
| Q55281004 | Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes. |
| Q35019550 | Nanomedical engineering: shaping future nanomedicines |
| Q91831250 | Nanoparticle-Based Contrast Agents for 129Xe HyperCEST NMR and MRI Applications |
| Q99712238 | Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance |
| Q35840361 | Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2. |
| Q45794953 | Naturally occurring phenolic acids modulate TPA-induced activation of EGFR, AP-1, and STATs in mouse epidermis. |
| Q38519582 | Necitumumab for non-small cell lung cancer |
| Q52957112 | Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer. |
| Q37890404 | Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development |
| Q39036930 | Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study |
| Q33579636 | Next generation of antibody therapy for cancer |
| Q34657670 | Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants. |
| Q52653066 | Nimotuzumab enhances the sensitivity of non-small cell lung cancer cells to tumor necrosis factor-α by inhibiting the nuclear factor-кB signaling pathway. |
| Q104073421 | Non-metabolic role of UCK2 links EGFR-AKT pathway activation to metastasis enhancement in hepatocellular carcinoma |
| Q37036792 | Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond |
| Q45864200 | Nonviral gene delivery to human ovarian cancer cells using arginine-grafted PAMAM dendrimer |
| Q41033340 | Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities |
| Q52599496 | Novel Systemic Therapies for Advanced Gastric Cancer. |
| Q35173073 | Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family |
| Q37772496 | Novel biomarkers of metastatic cancer |
| Q37487981 | Novel chemotherapy approaches for cervical cancer. |
| Q37622196 | Novel combination markers for predicting survival in patients with muscle invasive bladder cancer: USP18 and DGCR2. |
| Q28386773 | Novel insights into the molecular origins and treatment of lung cancer |
| Q38615458 | Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: impact on gastrointestinal cancers driven by secondary bile acids. |
| Q38019657 | Novel targeted agents for gastric cancer |
| Q41953402 | Nuclear EGFR is required for cisplatin resistance and DNA repair |
| Q37282661 | Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer |
| Q40549193 | Nuclear factor kappa B (NFkappaB) dependent modulation of Epstein-Barr virus latent membrane protein 1 (LMP1) in epidermal growth factor receptor (EGFR) promoter activity |
| Q38810432 | Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival |
| Q39399252 | Nuclear translocation of pro-amphiregulin induces chemoresistance in gastric cancer. |
| Q37529397 | Oestrogen receptor negativity in breast cancer: a cause or consequence? |
| Q41144916 | Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation |
| Q38844554 | Oncogenic MCT-1 activation promotes YY1-EGFR-MnSOD signaling and tumor progression |
| Q37745280 | Oncogenic role of rab escort protein 1 through EGFR and STAT3 pathway |
| Q35569418 | One target, different effects: a comparison of distinct therapeutic antibodies against the same targets |
| Q49818115 | Optical molecular imaging for tumor detection and image-guided surgery. |
| Q36499255 | Optimal treatment of metastatic colorectal cancer |
| Q46427814 | Organometallic cobalamin anticancer derivatives for targeted prodrug delivery via transcobalamin-mediated uptake |
| Q55223569 | Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway. |
| Q38945259 | Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy |
| Q39690576 | Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway |
| Q45232514 | Overexpression of EphB4, EphrinB2, and epidermal growth factor receptor in papillary thyroid carcinoma: A pilot study |
| Q47793305 | Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I-II colon cancer patients |
| Q40125752 | Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease |
| Q45875804 | Oxymatrine inhibits non-small cell lung cancer via suppression of EGFR signaling pathway |
| Q37013280 | PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations |
| Q34996125 | PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation |
| Q58110132 | PET Imaging Biomarkers of Anti-EGFR Immunotherapy in Esophageal Squamous Cell Carcinoma Models |
| Q34429075 | PET of EGFR expression with an 18F-labeled affibody molecule |
| Q54227938 | PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel. |
| Q39826662 | PKC-delta binds to E-cadherin and mediates EGF-induced cell scattering |
| Q36199783 | PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis |
| Q38354856 | Pancreatic cancer: diagnosis and treatments |
| Q88790399 | Past, present and future of gene expression-tailored therapy for lung cancer |
| Q37389526 | Pathogenesis of lung cancer signalling pathways: roadmap for therapies |
| Q90332238 | Peptide-Au Cluster Probe: Precisely Detecting Epidermal Growth Factor Receptor of Three Tumor Cell Lines at a Single-Cell Level |
| Q33870552 | Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion |
| Q38869428 | Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors |
| Q26774521 | Personalized medicine in gastric cancer: Where are we and where are we going? |
| Q37170005 | Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma |
| Q37112320 | Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice |
| Q40077599 | Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor |
| Q45141053 | Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects |
| Q42595256 | Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. |
| Q43181709 | Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). |
| Q35154219 | Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study |
| Q54403335 | Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics. |
| Q36717778 | Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer |
| Q39561256 | Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells |
| Q36235303 | Phosphorylation is the switch that turns PEA-15 from tumor suppressor to tumor promoter |
| Q35590357 | Phosphorylation of PCNA by EGFR inhibits mismatch repair and promotes misincorporation during DNA synthesis |
| Q38900907 | Photoacoustic Imaging in Oncology: Translational Preclinical and Early Clinical Experience |
| Q26861053 | Plant sterols as anticancer nutrients: evidence for their role in breast cancer |
| Q33824400 | Polymeric Nanoparticle-Mediated Gene Delivery for Lung Cancer Treatment |
| Q36046346 | Polymorphism in epidermal growth factor is related to clinical outcomes of metastatic colorectal cancer patients treated with cetuximab: a systematic review and meta-analysis |
| Q36385082 | Polymorphisms in intron 1 of the EGFR gene in non-small cell lung cancer patients |
| Q35538464 | Potential antitumor therapeutic application of Grimontia hollisae thermostable direct hemolysin mutants |
| Q35137787 | Potential roles of Centipede Scolopendra extracts as a strategy against EGFR-dependent cancers |
| Q36532110 | Potential use of humanized antibodies in the treatment of breast cancer. |
| Q37075379 | Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake. |
| Q39297048 | Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck |
| Q37138420 | Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy |
| Q36788485 | Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. |
| Q30364872 | Probing the Heterogeneity of Protein Kinase Activation in Cells by Super-resolution Microscopy |
| Q36880902 | Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma |
| Q36082772 | Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis. |
| Q34086636 | Prognostic biomarkers in ovarian cancer |
| Q55059350 | Prognostic factors and genes associated with endometrial cancer based on gene expression profiling by bioinformatics analysis. |
| Q44468300 | Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection |
| Q43631346 | Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis |
| Q51393573 | Prognostic significance of cyclooxygenase-2, epidermal growth factor receptor 1, and microvascular density in gastric cancer. |
| Q55209158 | Prognostic significance of epidermal growth factor receptor (EGFR) over expression in urothelial carcinoma of urinary bladder. |
| Q36293820 | Prognostic value of epidermal growth factor receptor expression in operable non-small cell lung carcinoma |
| Q37468304 | Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors |
| Q46610690 | Prognostic value of immunohistochemical expression profile of epidermal growth factor receptor in urothelial bladder cancer |
| Q40265329 | Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells |
| Q39235953 | Prolonged exposure to acid and bile induces chromosome abnormalities that precede malignant transformation of benign Barrett's epithelium |
| Q36235591 | Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity |
| Q38084617 | Promising new molecular targeted therapies in head and neck cancer |
| Q43743711 | Promising newer molecular-targeted therapies in head and neck cancer |
| Q33711287 | Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma |
| Q24677062 | Prostasin induces protease-dependent and independent molecular changes in the human prostate carcinoma cell line PC-3 |
| Q91866079 | Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery |
| Q53598605 | Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. |
| Q37417742 | Protein kinase inhibitors: contributions from structure to clinical compounds |
| Q51540449 | Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. |
| Q24337213 | Protein phosphorylation profiling using an in situ proximity ligation assay: phosphorylation of AURKA-elicited EGFR-Thr654 and EGFR-Ser1046 in lung cancer cells |
| Q33820267 | Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression |
| Q33275224 | Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma |
| Q92192845 | Proteomics and Non-proteomics Approaches to Study Stable and Transient Protein-Protein Interactions |
| Q52663650 | Proteomics reveals novel protein associations with early endosomes in an epidermal growth factor-dependent manner. |
| Q89687320 | Proximate Analysis and Safety Profile of Farmed Edible Bird's Nest in Malaysia and Its Effect on Cancer Cells |
| Q35584250 | Quality of Life in Hormone Receptor–Positive HER-2+ Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib |
| Q36813117 | Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging |
| Q41997137 | Quantitative Analysis of ErbB1 and ErbB2 Genes Amplification by a High Performance Liquid Chromatography |
| Q47748669 | Quantum-Dot-Based Theranostic Micelles Conjugated with an Anti-EGFR Nanobody for Triple-Negative Breast Cancer Therapy. |
| Q35051834 | RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer |
| Q33648830 | RHBDD1 upregulates EGFR via the AP-1 pathway in colorectal cancer |
| Q33569727 | RNA interference and nonviral targeted gene therapy of experimental brain cancer |
| Q53265601 | Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model. |
| Q33872030 | Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer |
| Q39706629 | Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein |
| Q30436623 | Rational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice. |
| Q33839177 | Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy |
| Q42918163 | Reactive oxygen species (ROS) reduce the expression of BRAK/CXCL14 in human head and neck squamous cell carcinoma cells |
| Q50186364 | Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery. |
| Q38899428 | Recent progress in protein-protein interaction study for EGFR-targeted therapeutics |
| Q90537630 | Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC |
| Q37118936 | Recurrent head and neck cancer: current treatment and future prospects. |
| Q35860644 | Recycling and Endosomal Sorting of Protease-activated Receptor-1 Is Distinctly Regulated by Rab11A and Rab11B Proteins. |
| Q37581161 | Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors |
| Q47747965 | Reduced bikunin gene expression as a factor of poor prognosis in ovarian carcinoma |
| Q35917427 | Reformulating Tylocrebrine in Epidermal Growth Factor Receptor Targeted Polymeric Nanoparticles Improves Its Therapeutic Index |
| Q36738312 | Regulation of MAPKs by growth factors and receptor tyrosine kinases |
| Q35971560 | Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer |
| Q38758386 | Regulatory mechanisms of EGFR signalling during Drosophila eye development |
| Q35602185 | Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies |
| Q36524455 | Revealing the role of VEGFA in clear cell sarcoma of the kidney by protein-protein interaction network and significant pathway analysis |
| Q37160382 | Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck |
| Q90411189 | Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy |
| Q36461805 | Review of the treatment of non-small cell lung cancer with gefitinib |
| Q38916329 | RhoC mediates epidermal growth factor-stimulated migration and invasion in head and neck squamous cell carcinoma |
| Q38761493 | Rinsing paired-agent model (RPAM) to quantify cell-surface receptor concentrations in topical staining applications of thick tissues |
| Q57918768 | Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese |
| Q60935640 | Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage |
| Q59137936 | Role of bile acids in colon carcinogenesis |
| Q35125750 | Role of systemic peri-operative chemotherapy in management of transitional cell carcinoma of bladder |
| Q35572905 | Role of traditional and new biomarkers in breast carcinogenesis. |
| Q39015239 | S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy. |
| Q26798149 | SAM68: Signal Transduction and RNA Metabolism in Human Cancer |
| Q39832417 | SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline |
| Q40009259 | SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression |
| Q73733584 | Screening for inducers of kinase degradation |
| Q34480613 | Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: another inflammation-cancer link. |
| Q36672321 | Secreted and O-GlcNAcylated MIF binds to the human EGF receptor and inhibits its activation |
| Q36616873 | Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib |
| Q30978860 | Selective regain of egfr gene copies in CD44+/CD24-/low breast cancer cellular model MDA-MB-468. |
| Q41476953 | Selective uptake of epidermal growth factor-conjugated gold nanoparticle (EGF-GNP) facilitates non-thermal plasma (NTP)-mediated cell death |
| Q35889589 | Sensitization of epithelial growth factor receptors by nicotine exposure to promote breast cancer cell growth |
| Q39000135 | Serine Protease Inhibitor Kazal Type 1 (SPINK1) Promotes Proliferation of Colorectal Cancer Through the Epidermal Growth Factor as a Prognostic Marker. |
| Q53202983 | Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy. |
| Q46946875 | Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas |
| Q37347517 | Sex disparities in the association of lung adenocarcinoma with colorectal cancer |
| Q35579617 | Signaling network state predicts twist-mediated effects on breast cell migration across diverse growth factor contexts |
| Q38776725 | Silencing TAK1 alters gene expression signatures in bladder cancer cells |
| Q57292420 | Simultaneous evaluation of anti-EGFR-induced tumour and adverse skin effects in a microfluidic human 3D co-culture model |
| Q40230093 | Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma |
| Q37228581 | Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors. |
| Q34710595 | Smart drugs: tyrosine kinase inhibitors in cancer therapy |
| Q37502708 | Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. |
| Q37252262 | Somatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas |
| Q99607554 | Somatic mutation detection efficiency in EGFR: a comparison between high resolution melting analysis and Sanger sequencing |
| Q24648133 | Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer |
| Q37235024 | Somatic pharmacogenomics in cancer |
| Q36436693 | Some p53-binding proteins that can function as arbiters of life and death. |
| Q47155647 | Sortilin limits EGFR signaling by promoting its internalization in lung cancer |
| Q36137109 | Spheroid Culture of Head and Neck Cancer Cells Reveals an Important Role of EGFR Signalling in Anchorage Independent Survival |
| Q33869194 | Spotlight on differentially expressed genes in urinary bladder cancer. |
| Q39677393 | Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells |
| Q38238743 | Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer |
| Q35017477 | Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay |
| Q40694780 | Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation |
| Q39188570 | Study on invadopodia formation for lung carcinoma invasion with a microfluidic 3D culture device |
| Q39554373 | Successful treatment of epidermal growth factor receptor inhibitor-induced alopecia with doxycycline |
| Q38955418 | Suppression of EGFR-STAT3 signaling inhibits tumorigenesis in a lung cancer cell line. |
| Q50493805 | Surface engineering of gold nanoparticles for in vitro siRNA delivery. |
| Q24309274 | Survival of cancer cells is maintained by EGFR independent of its kinase activity |
| Q42726557 | Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction |
| Q33637787 | Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells |
| Q54347509 | Synthesis of caffeic acid amides bearing 2,3,4,5-tetra-hydrobenzo[b][1,4]dioxocine moieties and their biological evaluation as antitumor agents. |
| Q38940074 | Synthetic genistein glycosides inhibiting EGFR phosphorylation enhance the effect of radiation in HCT 116 colon cancer cells. |
| Q92856034 | TGF-β1 mediates lncRNA GAPLINC expression to promote the migration and invasion of non-small cell lung cancer |
| Q35381933 | TNFα-mediated loss of β-catenin/E-cadherin association and subsequent increase in cell migration is partially restored by NKX3.1 expression in prostate cells |
| Q36956724 | Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer |
| Q40512067 | Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). |
| Q37795802 | Targeted Agents in Ovarian Cancer |
| Q90478729 | Targeted Delivery of 111In Into the Nuclei of EGFR Overexpressing Cells via Modular Nanotransporters With Anti-EGFR Affibody |
| Q33664307 | Targeted Therapy of Cancer Using Photodynamic Therapy in Combination with Multi-faceted Anti-Tumor Modalities |
| Q36920799 | Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives |
| Q36659265 | Targeted coating with antigenic peptide renders tumor cells susceptible to CD8(+) T cell-mediated killing |
| Q36054970 | Targeted therapies for lung cancer: clinical experience and novel agents |
| Q37290448 | Targeted therapies in the management of metastatic bladder cancer |
| Q39213693 | Targeted therapies in the treatment of urothelial cancers |
| Q38815297 | Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). |
| Q36294579 | Targeted therapy in gastroesophageal cancers: past, present and future |
| Q36957757 | Targeted therapy in rectal cancer. |
| Q52676608 | Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer. |
| Q36429516 | Targeting HER1/EGFR in cancer therapy: experience with erlotinib |
| Q34495463 | Targeting angiogenesis with integrative cancer therapies |
| Q40751673 | Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. |
| Q51060657 | Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells. |
| Q36400144 | Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro |
| Q36123983 | Targeting polyIC to EGFR over-expressing cells using a dsRNA binding protein domain tethered to EGF. |
| Q36913614 | Targeting signaling pathways in epithelial ovarian cancer |
| Q37600910 | Targeting the EGF receptor ectodomain in the context of cancer |
| Q38757863 | Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab |
| Q36564975 | Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. |
| Q35982925 | The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. |
| Q36803187 | The Chicago Thoracic Oncology Database Consortium: A Multisite Database Initiative |
| Q49544424 | The Dawning of Translational Breast Cancer: From Bench to Bedside |
| Q49887941 | The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells. |
| Q92839866 | The RNA-binding protein Sam68 is critical for non-small cell lung cancer cell proliferation by regulating Wnt/β-catenin pathway |
| Q60960084 | The Use of HPV16-E5, EGFR, and pEGFR as Prognostic Biomarkers for Oropharyngeal Cancer Patients |
| Q35376123 | The cannabinoid receptor inverse agonist AM251 regulates the expression of the EGF receptor and its ligands via destabilization of oestrogen-related receptor α protein |
| Q33786779 | The cooperation between hMena overexpression and HER2 signalling in breast cancer |
| Q33618747 | The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC. |
| Q35247181 | The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells |
| Q35996651 | The current state of targeted agents in rectal cancer |
| Q36842728 | The developing trend of monoclonal antibodies in the treatment of colorectal cancer |
| Q28242493 | The emerging era of genomic data integration for analyzing splice isoform function |
| Q34343043 | The emerging role of nimotuzumab in the treatment of non-small cell lung cancer |
| Q38697702 | The enhanced tumor inhibitory effects of gefitinib and L-ascorbic acid combination therapy in non-small cell lung cancer cells |
| Q35546542 | The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells |
| Q34363400 | The epidermal growth factor receptor family in breast cancer |
| Q41721652 | The epigenetic regulation of CXCL14 plays a role in the pathobiology of oral cancers |
| Q90685224 | The inhibitory effect of ECG and EGCG dimeric procyanidins on colorectal cancer cells growth is associated with their actions at lipid rafts and the inhibition of the epidermal growth factor receptor signaling |
| Q35120839 | The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery |
| Q36201667 | The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies |
| Q45288154 | The pathologist and EGFR in 2004: I like you, nor do it |
| Q47952691 | The potential for cancer combination therapy with multi-targeted, single-protein pharmaceuticals |
| Q81408492 | The presence of carboxypeptidase-M in tumour cells signifies epidermal growth factor receptor expression in lung adenocarcinomas: the coexistence predicts a poor prognosis regardless of EGFR levels |
| Q33725976 | The quest to overcome resistance to EGFR-targeted therapies in cancer |
| Q49887915 | The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer |
| Q35094666 | The role of receptor tyrosine kinase inhibition in treating gastrointestinal malignancy |
| Q34902490 | The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells |
| Q36583507 | The role of the epidermal growth factor receptor in breast cancer |
| Q38337192 | The route to personalized medicine in bladder cancer: where do we stand? |
| Q38706625 | The size-speed-force relationship governs migratory cell response to tumorigenic factors. |
| Q37086390 | The status and role of ErbB receptors in human cancer. |
| Q37496695 | The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status. |
| Q35674177 | Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer |
| Q39345120 | Therapeutic and preventive effects of an epidermal growth factor receptor inhibitor on oral squamous cell carcinoma |
| Q37137412 | Therapeutic approaches to target cancer stem cells |
| Q37310694 | Therapeutic strategy for treatment of metastatic non-small cell lung cancer |
| Q39170938 | Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway |
| Q35530090 | Time-domain microfluidic fluorescence lifetime flow cytometry for high-throughput Förster resonance energy transfer screening |
| Q36557067 | Tissue-specific control of brain-enriched miR-7 biogenesis |
| Q92170097 | Transcriptome responses in blood reveal distinct biological pathways associated with arsenic exposure through drinking water in rural settings of Punjab, Pakistan |
| Q33747400 | Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. |
| Q37218978 | Treatment of recurrent metastatic head and neck cancer: focus on cetuximab |
| Q34569071 | Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. |
| Q33700990 | Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression |
| Q37049920 | Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial |
| Q37075319 | Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5. |
| Q36402296 | Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer |
| Q58700887 | Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles |
| Q28115136 | Tumor-suppressive miR-218-5p inhibits cancer cell proliferation and migration via EGFR in non-small cell lung cancer |
| Q82758574 | Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy |
| Q37338160 | Tumor-targeted delivery of siRNA by self-assembled nanoparticles |
| Q38718038 | Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery. |
| Q36218880 | Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity |
| Q42533211 | Tyrosine kinase receptor EGFR regulates the switch in cancer cells between cell survival and cell death induced by autophagy in hypoxia |
| Q54406282 | Up-regulation of EGF receptor and its ligands, AREG, EREG, and HB-EGF in oral lichen planus. |
| Q91826199 | Upregulation of SNX5 predicts poor prognosis and promotes hepatocellular carcinoma progression by modulating the EGFR-ERK1/2 signaling pathway |
| Q36785507 | Upregulation of epidermal growth factor receptor 4 in oral leukoplakia |
| Q35172558 | Urothelial carcinomas: a focus on human epidermal receptors signaling |
| Q30511916 | Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging |
| Q37354097 | Using the theory of coevolution to predict protein-protein interactions in non-small cell lung cancer. |
| Q37301478 | VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab |
| Q40351380 | Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies |
| Q34296399 | Variability in melanoma metalloproteinase expression profiling |
| Q78892615 | Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis |
| Q47110408 | Volume doubling time of lung adenocarcinomas considering epidermal growth factor receptor mutation status of exon 19 and 21: three-dimensional volumetric evaluation |
| Q86741221 | WITHDRAWN: Improved therapeutic effectiveness by combining recombinant p14ARF with antisense complementary DNA of EGFR in laryngeal squamous cell carcinoma |
| Q37933675 | When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression |
| Q31150111 | Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells |
| Q24318720 | ZIP: a novel transcription repressor, represses EGFR oncogene and suppresses breast carcinogenesis |
| Q41686713 | ZNF516 suppresses EGFR by targeting the CtBP/LSD1/CoREST complex to chromatin |
| Q54584675 | [Expressions of c-Cbl, Cbl-b and EGFR and its role of prognosis in NSCLC]. |
| Q79405797 | [Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid] |
| Q79328028 | [Transitional bladder carcinoma TaG1: role of the EGFr tyrosin kinase activation in the cellular proliferation] |
| Q81771221 | [Tumor markers and biomarkers in squamous cell cancer of the head and neck] |
| Q33384492 | c-Fos overexpression increases the proliferation of human hepatocytes by stabilizing nuclear Cyclin D1 |
| Q44184282 | gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. |
| Q40068432 | her-2 upstream open reading frame effects on the use of downstream initiation codons |
| Q36132797 | miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma |
| Q38857823 | miR-133a inhibits cervical cancer growth by targeting EGFR. |
| Q47752840 | miR-202 inhibits cell proliferation, migration, and invasion by targeting EGFR in human bladder cancer |
| Q39373570 | p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway |
| Q39706021 | p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signalling in tumour cell scatter and proliferation. |
| Q92422648 | p21cip1/waf1 Coordinate Autophagy, Proliferation and Apoptosis in Response to Metabolic Stress |
| Q34583151 | p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study |
| Q54194507 | pH dependence of ligand-induced human epidermal growth factor receptor activation investigated by molecular dynamics simulations. |
| Q33825091 | sZIP, an alternative splice variant of ZIP, antagonizes transcription repression and growth inhibition by ZIP |
| Q36791813 | shRNA and siRNA delivery to the brain |